KRAS and non-small cell lung carcinoma: Since EGFR and KRAS mutations in NSCLC are generally considered mutually exclusive, we propose that LUAD tissues with WT EGFR and mutant KRAS may exhibit higher ADAM9 expression compared to tissues with mutant EGFR.